Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

STREPSYNTH · Rewiring the Streptomyces cell factory for cost-effective production of biomolecules

FP7Status: CLOSED1 December 201330 November 2018EU funding €8,691,070

STREPSYNTH aims to set-up a Streptomyces-based new industrial production platform (SNIP) for high value added biomolecules. Streptomyces lividans was chosen as a bacterial host cell because it has been already shown to be highly efficient for the extracellular production of a number of heterologous molecules that vary chemically, has a robust tradition of industrial fermentation and is fully accessible to genetic intervention. To develop SNIP our strategy has two components: first, we will construct a collection of reduced-genome S. lividans strains. This will metabolically streamline the cell and rid it of agents (e.g. proteases) of potential harm to the heterologous polypeptides. Second, we will engineer synthetic parts and cassettes, i.e. reshuffled, rewired and repurposed genetic elements either indigenous to S. lividans or heterologous genes organized in artificial operon clusters. These elements will serve three aims: transcriptional and translational optimization, sophisticated on-demand transcriptional regulation that will provide unique fermentation control and metabolic engineering of complete cellular pathways channeling biomolecules to profuse extracellular secretion. Synthetic parts and cassettes will be either directly incorporated into the genome or be hosted in the form of plasmids. Systems biology tools will guide fine-tuning rounds of cell factory engineering and fermentation optimization. To set up SNIP we chose two classes of biomolecules with obvious immediate industrial value and application: heterologous proteins (industrial enzymes, biopharmaceuticals, biofuel enzymes, diagnostics) and small molecules (lantipeptides and indolocarbozoles) useful for multiple industrial purposes (biopharmaceuticals, additives, food technology, bioenergy). These biomolecules are of immediate interest to SMEs that participate and guide the industrial relevance of STREPSYNTH. SNIP is a modular platform that can be repurposed for diverse future applications.

Consortium · 17 organisations

coordinator

KATHOLIEKE UNIVERSITEIT LEUVEN

BE · €1,643,099

participant

PROGENUS SA

BE · €463,700

participant

THE UNIVERSITY OF MANCHESTER

UK · €320,223

participant

ENTRECHEM SL

ES · €596,450

participant

FORSCHUNGSZENTRUM JULICH GMBH

DE · €264,031

participant

PHARMABIOTEC GMBH

DE · €128,808

participant

UNIVERSITAT WIEN

AT · €425,490

participant

Q-BIOLOGICALS NV

BE · €1,042,070

participant

IDRYMA TECHNOLOGIAS KAI EREVNAS

EL · €251,170

participant

MATIS OHF

IS · €280,290

participant

USTAV MOLEKULARNEJ BIOLOGIE SLOVENSKEJ AKADEMIE VIED

SK · €183,680

participant

TECHNISCHE UNIVERSITAT BERLIN

DE · €777,550

participant

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

DE · €594,794

participant

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

IL · €481,650

participant

UNIVERSITAET BIELEFELD

DE · €578,500

participant

NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU

NO · €353,115

participant

APRONEX S.R.O

CZ · €306,450

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.